Nikolay Novitski/LinkedIn
May 5, 2026, 16:28
Nikolay Novitski: A New Era in Cardiovascular Prevention
Nikolay Novitski, Deputy chief physician, Associate professor Kaluga university, Board member Russian HF society, shared a post on X:
”Lipoprotein(a), or Lp(a), is an important cardiovascular risk factor that is largely unaffected by lifestyle changes or statin therapy.
Emerging therapies include:
- Pela (ASO) – approximately an 80 percent reduction (expected in 2026)
- Olpa (siRNA) – approximately a 71 to 101 percent reduction (expected in 2026)
- Lepo (siRNA) – approximately a 94 percent reduction, with effects lasting up to 1.5 years after a single injection
- Muva (oral) – approximately an 86 percent reduction in Lp(a)
Important note:
- Very low Lp(a) levels may be associated with an increased risk of type 2 diabetes.”
Stay updated with Hemostasis Today.
-
Jun 26, 2026, 13:58Peter Bou Dib: How Factor IX Transformed Hemophilia B Treatment
-
Jun 26, 2026, 13:49Raghavendra Rao: The Surprising Link Between Chronic Venous Insufficiency and Falls
-
Jun 26, 2026, 13:40Caylynn Carls: Why Genetic Counseling Matters in Hemophilia Treatment
-
Jun 26, 2026, 13:25Ángel Cabrera: Clotting Disorders Behind Heavy Menstrual Bleeding
-
Jun 26, 2026, 13:02Turid Kjellevold: The Critical Role of Timely Hemostasis Testing
-
Jun 26, 2026, 10:59Wolfgang Miesbach: How Clonal Hematopoiesis May Explain Age-Related Mitochondrial Mutations
-
Jun 26, 2026, 10:52Chinua Onyebuchi: The Future of Stroke Care in Africa Lies in Strong Health Systems
-
Jun 26, 2026, 10:35Habtamu Milkias Wolde: New Insights into Stroke and Traumatic Brain Injury from Global Burden of Disease Data
-
Jun 26, 2026, 10:19Rytis Masiliūnas: Atrial Fibrillation and Stroke Care Disparities Across the Baltic Region